吉妥珠单抗奥唑米星治疗急性髓系白血病。

Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia.

作者信息

Stadtmauer Edward A

机构信息

Bone Marrow and Stem Cell Transplant Program, University of Pennsylvania Cancer Center, 16 Penn Tower, 3400 Spruce Street, Philadelphia, PA 19104, USA.

出版信息

Curr Oncol Rep. 2002 Sep;4(5):375-80. doi: 10.1007/s11912-002-0030-2.

DOI:10.1007/s11912-002-0030-2

PMID:12162910

Abstract

Options for treatment of poor-prognosis or relapsed acute myeloid leukemia (AML) remain limited. Gemtuzumab ozogamicin (Mylotarg, Wyeth-Ayerst, Philadelphia, PA) is an immunoconjugate composed of recombinant humanized murine anti-CD33 antibody linked to calicheamicin, a potent cytotoxic agent. Phase II trials have shown the efficacy of gemtuzumab ozogamicin in the treatment of relapsed AML. Trials exploring this agent in other CD33+ hematologic malignancies and in combination with other agents for AML are ongoing. Gemtuzumab ozogamicin is associated with acceptable toxicity as a single agent. However, the incidence of veno-occlusive disease of the liver remains a concern when this agent is used in combination with chemotherapy or in the context of hematopoietic stem cell transplant.

摘要

预后不良或复发的急性髓系白血病（AML）的治疗选择仍然有限。吉妥单抗奥唑米星（Mylotarg，惠氏-艾尔斯特公司，宾夕法尼亚州费城）是一种免疫偶联物，由重组人源化鼠抗CD33抗体与强力细胞毒性药物卡奇霉素连接而成。II期试验已显示吉妥单抗奥唑米星治疗复发AML的疗效。正在进行在其他CD33+血液系统恶性肿瘤中探索该药物以及与其他药物联合用于AML的试验。吉妥单抗奥唑米星作为单一药物时具有可接受的毒性。然而，当该药物与化疗联合使用或在造血干细胞移植的情况下使用时，肝静脉闭塞性疾病的发生率仍然令人担忧。